Sunovion Pharmaceuticals Inc.
84 Waterford Drive
About Sunovion Pharmaceuticals Inc.
Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people living with serious medical conditions. Our vision is to lead the way to a healthier world, and we believe scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything we do, we have charted new paths to life-transforming treatments reflecting ongoing investments in R&D and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.
324 articles with Sunovion Pharmaceuticals Inc.
Sunovion Announces Acceptance by the U.S. FDA of the New Drug Application for Dasotraline for the Treatment of Adults with Moderate-to-Severe Binge Eating Disorder
Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for dasotraline, a novel dopamine and norepinephrine reuptake inhibitor (DNRI), for the treatment of patients with moderate-to-severe binge eating disorder (BED).
AMSA and Sunovion Partner to Inspire Next Generation of Innovators, Provide Students With Opportunity to Teach Neuroscience to Their Classmates
Five AMSA upper school level students, four seniors and one junior, were selected as a team to participate in this collaborative project with Sunovion for their school’s Capstone Project.
Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia
Sunovion Pharmaceuticals Inc. (Sunovion) and PsychoGenics Inc. (PsychoGenics), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for SEP-363856, a novel agent for the treatment of people with schizophrenia.
Sunovion Highlights Data from Its Psychiatry Portfolio at the 2019 American Psychiatric Association Annual Meeting
2019 American Psychiatric Association (APA 2019) Annual Meeting, which will be held May 18-22, in San Francisco, Calif.
Sunovion to Present Data on LONHALA® MAGNAIR® Inhalation Solution and COPD at the American Thoracic Society International Conference 2019
Sunovion Pharmaceuticals Inc. (Sunovion) will present data from its portfolio of treatments for chronic obstructive pulmonary disease (COPD) at the American Thoracic Society International Conference 2019 (ATS 2019), taking place May 17-22, 2019 in Dallas, Texas.
Sunovion Pharmaceuticals Inc. announced the appointment of Antony Loebel, M.D., to the role of President and Chief Executive Officer, effective April 1, 2019.
Aquestive Therapeutics Provides Update on Licensee, Sunovion Pharmaceuticals Inc.'s Apomorphine Sublingual Film (APL-130277) New Drug Application
APL-130277 is a medicine to treat OFF episodes (the re-emergence or worsening of Parkinson's symptoms otherwise controlled by medications) experienced by people living with Parkinson's disease
Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration issued a Complete Response Letter for the New Drug Application for apomorphine sublingual film to treat OFF episodes experienced by people living with Parkinson’s disease.
The regulatory agency issued a Complete Response Letter to the Marlborough, Mass.-based Sunovion, the company said this morning. After reviewing the New Drug Application, the FDA said it could not approve the application for the apomorphine sublingual film in its present form.
Sunovion and PsychoGenics Announce Positive Results from Pivotal Phase 2 Study of Novel Investigational Agent SEP-363856 for the Treatment of Schizophrenia
SEP-363856 was identified through a collaboration between Sunovion and PsychoGenics
AstraZeneca is unloading rights to Alvesco (ciclesonide) to treat persistent asthma, and Omnaris and Zetonna (ciclesonide) to treat nasal symptoms associated with rhinitis. The company indicates that the rights cover markets outside the United States and the U.S. royalties for the drugs.
Kedalion Therapeutics, Inc. today announced the hiring of medical device industry veteran Reynaldo Quintana as Vice President of Engineering.
Sunovion Announces Health Canada Approval of Aptiom® (eslicarbazepine acetate) as Adjunctive Therapy for the Treatment of Partial-Onset Seizures in Adolescents and Children Above Six Years of Age
APTIOM provides an important new treatment option for adolescents and children above six years of age with partial-onset seizures
Sunovion Announces Positive Top-Line Results from Pivotal Study Evaluating Dasotraline in Adults with Binge Eating Disorder
Study met its primary endpoint demonstrating fewer binge days per week with dasotraline versus placebo in the treatment of adults with moderate to severe binge eating disorder.
Sunovion to Launch Take On Tomorrow™ Giving Opportunity with Red Sox Foundation and 7th Annual Community Service Program
Expecting to Reach 25,000 Cumulative Employee Volunteer Hours This Summer, Company Will Mark Milestone by Donating $25,000 to Support Education and Mental Health Initiatives
As Treatments Await FDA Ruling, Researchers Discover ‘Key Players’ in Early-Onset Parkinson’s Dis...
6/15/2018While pharma and biotech researchers have been driving forward with therapies aimed at helping Parkinson’s disease patients, medical researchers have identified “unexpected new key players” in the development of early-onset Parkinson’s disease, called Parkinsonism.
Sunovion Announces FDA Acceptance of New Drug Application for Apomorphine Sublingual Film (APL-130277)
Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for apomorphine sublingual film (APL-130277)
Approximately 25 percent of adults in the United States will deal with some form of mental illness within a given year. It’s also estimated that many of the people who experience these problems may never report it or seek help.
Sunovion to Deliver Multiple Presentations at the 2018 American Psychiatric Association Annual Meeting
– New data analyses highlight the use of Latuda® (lurasidone HCl) in pediatric populations, including long-term efficacy and safety outcomes in bipolar depression and schizophrenia – – Further data on use of dasotraline in children and adults with ADHD and adults with binge eating disorder (BED) will be presented –
Sunovion Announces Lonhala™ Magnair™ (glycopyrrolate) Inhalation Solution Now Available in the U.S. for the Treatment of COPD
LONHALA MAGNAIR is the first nebulized long-acting muscarinic antagonist (LAMA) available for the treatment of COPD in the U.S.